MacroGenics is a biopharmaceutical company that specializes in developing innovative monoclonal antibody-based therapeutics, particularly for cancer treatment. The company employs advanced technologies such as Antibody Drug Conjugates (ADCs) and bispecific checkpoint inhibitors. ADCs, like vobramitamab duocarmazine, utilize a deep understanding of disease biology and protein engineering to create targeted therapies that selectively kill cancer cells by leveraging proprietary linker payloads. Additionally, MacroGenics' DART® and TRIDENT® platforms facilitate the development of bispecific antibodies that can bind to multiple targets simultaneously, enhancing the therapeutic effect compared to traditional single-target antibodies. This approach aims to improve efficacy and safety while simplifying clinical development.

Furthermore, MacroGenics is advancing next-generation T-cell engagers, exemplified by MGD024, which are designed to redirect T-cell activation against cancer cells. These engagers can recruit various cytotoxic T cells and trigger their activation to effectively destroy cancer cells. Importantly, the design of these T-cell engagers incorporates a CD3 component that aims to reduce the risk of cytokine-release syndrome, a serious side effect associated with T-cell therapies, while enhancing antitumor activity and allowing for more manageable dosing schedules. Through these innovative technologies, MacroGenics is committed to addressing unmet medical needs in oncology.

United States

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.



Cancer

Endocrine System Diseases

Immune System Diseases

Lung Diseases

Metabolic Diseases

Urogenital Diseases

MacroGenics

Breast cancer

Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).

MARGENZA (Margetuximab) (Fc-engineered, anti-HER2 mAb)

Metastatic merkel cell carcinoma

Skin cancer

Solid tumor/s

Marketed antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the “brakes” on the immune system that are often imposed by tumors as a means to evade immune detection. Retifanlimab (formerly MGA012) is a humanized, proprietary anti-PD-1 monoclonal antibody being developed for use as monotherapy as well as in combination with other potential cancer therapeutics. Retifanlimab was licensed to Incyte Corporation in 2017 under a global collaboration and license agreement.

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) 

Anal cancer

Lung cancer

Non-small cell lung carcinoma

Retifanlimab (anti-PD-1 mAb)

Castration-resistant prostate cancer

MGC018 is an ADC comprised of an anti-B7-H3 humanized IgG1/kappa &nbsp;monoclonal antibody conjugated via a cleavable linker to the prodrug &nbsp;seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), &nbsp;with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an &nbsp;alkylating agent that can damage DNA in both dividing and non-dividing &nbsp;cells, causing cell death. B7-H3 is a molecule highly expressed on many &nbsp;solid tumors and associated with a poor clinical outcome. MGC018 is &nbsp;being evaluated in a Phase 1 study (<a href="https://www.globenewswire.com/Tracker?data=72Ccbbs5cFJZfFJ6mzi6MijtlGqzxOdsW59HNDaIw06luo9zeoObjdDh1algX98o-rZqXBNP-o1B1FkRrYMuDfu_reVFcljkuGMoMfq8PDcq7mKxeP9ZnP1HThZA5Sai" rel="nofollow" target="_blank">NCT03729596</a>). MacroGenics retains worldwide rights to MGC018.

Vobramitamab duocarmazine (vobra duo) (MGC018)

Lorigerlimab (previously known as MGD019) is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.

Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel

Prostate cancer

Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics’ Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer.

Enoblituzumab (anti-B7-H3)  

Platinum-resistant ovarian cancer

Lorigerlimab (previously known as MGD019) is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.

Lorigerlimab monotherapy

Acute myeloid leukemia

Myelodysplastic syndrome

MGD024 is a next-generation, humanized CD123 × CD3 DART molecule designed to minimize cytokine-release syndrome while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life.

MGD024

MGC026 is a clinical B7-H3-targeting ADC that is site-specifically conjugated to exatecan, a topoisomerase I inhibitor payload developed by Synaffix (a Lonza company)

MGC026

Gastric cancer

Margetuximab (Fc-engineered, anti-HER2 mAb)

Multiple myeloma

Flotetuzumab is a humanized DART® molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, has been reported to be over-expressed on cancer cells in a wide range of hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding hematopoietic progenitors and stem cell populations in normal human bone marrow.

Flotetuzumab (bispecific CD123 × CD3 DART molecule)

Head and neck squamous cell carcinoma

Enoblituzumab (anti-B7-H3) 

Melanoma

Triple-negative breast cancer

MGC018 is an ADC comprised of an anti-B7-H3 humanized IgG1/kappa &nbsp;monoclonal antibody conjugated via a cleavable linker to the prodrug &nbsp;seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), &nbsp;with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an &nbsp;alkylating agent that can damage DNA in both dividing and non-dividing &nbsp;cells, causing cell death. B7-H3 is a molecule highly expressed on many &nbsp;solid tumors and associated with a poor clinical outcome. MGC018 is &nbsp;being evaluated in a Phase 1 study (<a href="https://www.globenewswire.com/Tracker?data=72Ccbbs5cFJZfFJ6mzi6MijtlGqzxOdsW59HNDaIw06luo9zeoObjdDh1algX98o-rZqXBNP-o1B1FkRrYMuDfu_reVFcljkuGMoMfq8PDcq7mKxeP9ZnP1HThZA5Sai" rel="nofollow" target="_blank">NCT03729596</a>). MacroGenics retains worldwide rights to MGC018.
 
Lorigerlimab (previously known as MGD019) is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.

MacroGenics

Company Details